Novo Nordisk Basic Shares Outstanding 2010-2024 | NVO
Novo Nordisk annual/quarterly basic shares outstanding history and growth rate from 2010 to 2024. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares.
- Novo Nordisk basic shares outstanding for the quarter ending September 30, 2024 were $4.453B, a 0.52% decline year-over-year.
- Novo Nordisk basic shares outstanding for the twelve months ending September 30, 2024 were $17.854B, a 0.8% decline year-over-year.
- Novo Nordisk annual basic shares outstanding for 2023 were $4.483B, a 1.06% decline from 2022.
- Novo Nordisk annual basic shares outstanding for 2022 were $4.531B, a 1.38% decline from 2021.
- Novo Nordisk annual basic shares outstanding for 2021 were $4.594B, a 1.59% decline from 2020.
Novo Nordisk Annual Basic Shares Outstanding
(Millions of US $) |
| 2023 |
$4,483 |
| 2022 |
$4,531 |
| 2021 |
$4,594 |
| 2020 |
$4,668 |
| 2019 |
$4,749 |
| 2018 |
$4,839 |
| 2017 |
$4,946 |
| 2016 |
$5,060 |
| 2015 |
$5,142 |
| 2014 |
$5,242 |
| 2013 |
$5,359 |
| 2012 |
$5,483 |
| 2011 |
$5,653 |
| 2010 |
$5,855 |
| 2009 |
$5,992 |
Novo Nordisk Quarterly Basic Shares Outstanding
(Millions of US $) |
| 2024-09-30 |
$4,453 |
| 2024-06-30 |
$4,458 |
| 2024-03-31 |
$4,460 |
| 2023-12-31 |
$4,483 |
| 2023-09-30 |
$4,477 |
| 2023-06-30 |
$4,490 |
| 2023-03-31 |
$4,499 |
| 2022-12-31 |
$4,531 |
| 2022-09-30 |
$4,523 |
| 2022-06-30 |
$4,538 |
| 2022-03-31 |
$4,554 |
| 2021-12-31 |
$4,594 |
| 2021-09-30 |
$4,584 |
| 2021-06-30 |
$4,610 |
| 2021-03-31 |
$4,615 |
| 2020-12-31 |
$4,668 |
| 2020-09-30 |
$4,658 |
| 2020-06-30 |
$4,680 |
| 2020-03-31 |
$4,698 |
| 2019-12-31 |
$4,749 |
| 2019-09-30 |
$4,738 |
| 2019-06-30 |
$4,760 |
| 2019-03-31 |
$4,781 |
| 2018-12-31 |
$4,839 |
| 2018-09-30 |
$4,828 |
| 2018-06-30 |
$4,852 |
| 2018-03-31 |
$4,875 |
| 2017-12-31 |
$4,946 |
| 2017-09-30 |
$4,931 |
| 2017-06-30 |
$4,960 |
| 2017-03-31 |
$4,992 |
| 2016-12-31 |
$5,060 |
| 2016-09-30 |
$5,053 |
| 2016-06-30 |
$5,073 |
| 2016-03-31 |
$5,089 |
| 2015-12-31 |
$5,142 |
| 2015-09-30 |
$5,132 |
| 2015-06-30 |
$5,156 |
| 2015-03-31 |
$5,193 |
| 2014-12-31 |
$5,242 |
| 2014-09-30 |
$5,228 |
| 2014-06-30 |
$5,258 |
| 2014-03-31 |
$5,285 |
| 2013-12-31 |
$5,359 |
| 2013-09-30 |
$5,335 |
| 2013-06-30 |
$5,377 |
| 2013-03-31 |
$5,416 |
| 2012-12-31 |
$5,483 |
| 2012-09-30 |
$5,446 |
| 2012-06-30 |
$5,491 |
| 2012-03-31 |
$5,567 |
| 2011-12-31 |
$5,576 |
| 2011-09-30 |
$5,635 |
| 2011-06-30 |
$5,691 |
| 2011-03-31 |
$5,716 |
| 2010-12-31 |
$5,727 |
| 2010-09-30 |
$5,776 |
| 2010-06-30 |
$5,840 |
| 2010-03-31 |
$5,930 |
| 2009-12-31 |
$5,899 |
| 2009-09-30 |
$5,964 |
| 2009-06-30 |
$6,030 |
| 2009-03-31 |
$6,074 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$469.216B |
$33.708B |
|
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
|
